TABLE 1.
Baseline characteristics of study participants
| Male# | Female ¶ | |||
| Salbutamol | Placebo | Salbutamol | Placebo | |
| Participants n | 12 | 9 | 10 | 9 |
| Age years | 26±5 | 25±4 | 24±3 | 25±2 |
| Height cm | 182±4 | 182±5 | 169±7 | 165±5 |
| Weight kg | 77.8±10.1 | 76.6±7.9 | 63.6±7.9 | 59.9±5.7 |
| Whole-body lean mass kg | 62.7±6.8 | 63.6±7.9 | 46.1±4.7 | 43.4±4.6 |
| Whole-body fat mass kg | 12.2±3.8 | 10.1±2.6 | 15.2±4.5 | 14.1±3.3 |
| Whole-body fat % | 16.1±3.5 | 13.8±3.7 | 24.6±5.0 | 24.4±5.1 |
| V′O2max mL·min−1 | 4589±602 | 4592±658 | 3424±348 | 3096±306 |
| V′O2max mL·min−1·kg−1 | 59.2±5.6 | 59.9±6.1 | 54.2±5.4 | 52.8±4.7 |
| Incremental exercise performance W | 378±48 | 375±28 | 282±28 | 262±18 |
| FVC L | 5.8±0.7 | 5.9±0.5 | 4.3±0.6 | 3.7±0.2 |
| FEV1 L | 4.8±0.6 | 4.8±0.3 | 3.4±0.4 | 3.1±0.2 |
| FEV1/FVC | 0.83±0.05 | 0.81±0.08 | 0.81±0.11 | 0.85±0.06 |
| Change in FEV1 after exercise % | −3.9±3.6 | −1.2±5.9 | −1.8±4.5 | 0.3±2.7 |
| Change in FEV1 after β2-agonist % | 0.5±3.0 | 3.9±4.3 | 2.6±4.2 | 2.7±2.2 |
Values are presented as mean±sd. Incremental exercise performance is the highest power output achieved during the ramp test to exhaustion. V′O2max : maximal oxygen uptake. FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s. #: n=21; ¶: n=19.